Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lidoderm in Painful Diabetic and Idiopathic Neuropathy
NCT00903851Phase 4Completed
- Sponsor
- Endo International plc
- Start
- Apr 2002
- Primary completion
- Jun 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lidocaine 10% oropharyngeal spray in diabetic neuropathy and idiopathic neuropathy, sponsored by Endo International plc. Primary endpoint: Mean change from baseline to Week 3 in average pain intensity as measured from patient diaries using Brief Pain Inventory Question 5. Started Apr 2002; status: completed.
02
Drugs
lidocaine 10% oropharyngeal spray
03
Conditions
diabetic neuropathyidiopathic neuropathy
Beyond the preview
Go deeper on NCT00903851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00903851.